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Abstract 34 
Long duration spaceflights reportedly induce immune dysregulation, which is considered a 35 
risk to astronaut safety and mission success. Recent studies have examined the impact of 36 
spaceflight on markers of adaptive and innate immunity, but no study to date has 37 
comprehensively evaluated humoral immunity and serological markers of B-cell function. 38 
The aim of this study was to characterize changes in B-cell numbers and phenotypes, along 39 
with plasma immunoglobulins and polyclonal free light chains (FLC) – near ‘real-time’ 40 
biomarkers of immunoglobulin synthesis – in response to a ~6-month mission to the 41 
International Space Station (ISS). Whole blood samples were collected before flight, during 42 
("Early flight", "Mid-flight" and "Late flight"), immediately upon return and during a recovery 43 
period (R+18, R+30/R+33 and R+60/R+66) from 23 ISS crewmembers. B-cell counts and 44 
phenotypes were measured throughout the duration of the mission, along with total plasma 45 
immunoglobulin (Ig) and FLC levels. There was no effect of spaceflight on the number and 46 
proportion of the different B-cell subsets. There was no difference in kappa FLC between pre-47 
flight samples and either in-flight or recovery samples (p>0.05), and only a marginal 48 
reduction was observed in lambda FLC levels upon return to Earth (p<0.05). Furthermore, 49 
IgG and IgM remained unchanged during and after spaceflight, when compared to pre-flight 50 
values (p>0.05). Of note, plasma IgA concentrations were elevated in-flight when compared 51 
to baseline and recovery values (p<0.05). These results indicate that B-cell homeostasis is 52 
maintained during long duration spaceflight, advocating for potential in-flight vaccination as 53 
viable countermeasures against viral reactivation during exploration-class missions. 54 
 55 
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1. Introduction 59 
Long duration spaceflights are associated with alterations to both innate and adaptive 60 
immunity (11, 24), including impaired cytokine response to antigenic stimuli (8, 49), NK cell 61 
cytotoxicity (46), neutrophil and monocyte oxidative burst capacity (30, 31), lymphocyte 62 
distribution and proliferative capacity (40). As exposure to pathogens (45) and rate of latent 63 
viral reactivations (35, 36) are known to increase in space, profound immune dysregulation 64 
would likely have great clinical and operational significance during perennial missions. 65 
Logistical constraints unique to spaceflight have compelled the majority of space immunology 66 
research to be collected using short-duration missions or by comparing pre to post-flight 67 
measures of immune function. While these studies provided valuable insights on the immune 68 
status of astronauts upon return on earth, the magnitude of immune alterations during 69 
spaceflight are less clear. Furthermore, few studies have attempted to comprehensively 70 
characterize B-cell and plasma cell homeostasis during orbital missions. 71 
Effective humoral immunity is of fundamental importance to ensure adequate destruction of 72 
extracellular pathogens and the control of intracellular viral infections. As such, humoral 73 
immunity relies on the induction of different effector functions to antibody production, and 74 
any alteration in B-cell production, ability to differentiate, and in immunoglobulin output 75 
from plasma cells could lead to profound immune dysregulation and potentially endanger 76 
crew safety. The use of ground-based analogs to spaceflight, including hind-limb unloading, 77 
has highlighted significant reductions in B-cell progenitor cells in the bone marrow of mice 78 
which led to reduced B lymphopoiesis (32). Furthermore, short duration spaceflight missions 79 
have been shown to negatively impact cell phenotypes in the bone marrow (41) and splenic 80 
B-cell counts in mice (21), while simulated microgravity reduces hematopoietic stem cell 81 
proliferation rate (42). Although these changes appear to promote reductions in 82 
immunoglobulin output in animals following spaceflight (33), without affecting the breadth 83 
of the immunoglobulin repertoire (58), they may not translate to humans, as pre-flight 84 
immunoglobulin levels remain unchanged in cosmonauts following 6 months in the 85 
International Space Station (ISS) (46). Considering that it has been suggested for exploration 86 
crewmembers to receive in-flight vaccination against certain latent herpesviruses, in order to 87 
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maintain optimal protection throughout the duration of a ~3-year mission (13), optimal B-cell 88 
homeostasis is likely to be of paramount importance to preserve vaccine response and 89 
crewmember health.  Unfortunately however, those studies failed to measure in-flight 90 
changes in B-cell phenotypes and immunoglobulin concentrations.  91 
A limitation of measuring intact circulating immunoglobulins, such as total plasma IgG, IgA 92 
and IgM concentrations, is their slow clearance via cellular catabolism which confers them a 93 
relatively long biological half-life (1-3 weeks) (16). As this limits assessment of shorter term 94 
changes to Ig production, plasma Free Light Chains (FLC), with a short half-life of 2-6 hours 95 
(16), are conventionally used for the diagnosis, prognostication and monitoring of plasma cell 96 
dyscrasias (43, 44). In this context, plasma immunoglobulin FLC are considered to be a 97 
sensitive barometer of plasma cell activation and immune competency (28, 39). 98 
Immunoglobulin FLCs are produced by activated plasma cells during antibody synthesis, at a 99 
rate influenced by the magnitude of immune activation (28, 57). Elevated FLC levels are 100 
indicative of inflammation and have been associated with metabolic disorders and Type 2 101 
Diabetes (4, 27), chronic low grade inflammation (6), myeloma (53), and mortality in the 102 
general population (17), while low levels identify immune suppression (28). Consequently, 103 
plasma immunoglobulin FLC are likely the ideal candidates to detect early immune-104 
suppression in astronauts, and characterizing the effects of long duration spaceflight on 105 
plasma immunoglobulin FLC is of paramount importance. 106 
The successful implementation of exploration-class missions to Mars or other near-Earth 107 
objects requires a better understanding of the impact of long-duration spaceflight on the 108 
immune system in order to evaluate the risks of crew adverse health events associated with 109 
immune dysregulations. The aim of this study was to assess the impact of long-duration 110 
spaceflight on B-cell and plasma cell homeostasis by comprehensively analyzing changes in 111 
B-cell number, phenotype and soluble markers of humoral function during a 6-month 112 
mission in the International Space Station. 113 
 114 
2. Materials and Methods 115 
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2.1 Subjects and Study Design 116 
Data for this study was collected from 2 independent NASA-funded studies: The “Integrated 117 
Immune” study conducted at NASA-JSC (PI: Crucian) and the “Salivary Markers” study 118 
conducted at the University of Houston (PI: Simpson). A total of 23 ISS crewmembers (15 from 119 
Integrated Immune and 8 from Salivary Markers) ranging in age from 37.0 to 57.0 years old (3 120 
women, age 47.1 ± 5.6 years) were enrolled in this study. The ISS crew were affiliated with the 121 
National Aeronautics and Space Administration (NASA), European Space Agency (ESA), 122 
Japanese Aerospace Exploration Agency (JAXA) or Canadian Space Agency (CSA) and 123 
participated in a 6-month mission to the ISS. Data were collected over 18 separate ISS missions. 124 
Additionally, 6 ground-based controls (1 woman, age 33.0 ± 7.1 years) were enrolled in this 125 
study as part of Salivary Markers to ensure assay validity. The Committees for the Protection 126 
of Human Subjects (CPHS) at Louisiana State University, at the University of Houston and at 127 
NASA JSC approved the study, and informed consent was obtained from all subjects.  128 
2.2 Sample Collection 129 
For both studies, plasma samples were collected in lithium heparin tubes and whole blood 130 
samples were collected in Acid-Citrate Dextrose (ACD) tubes for cellular phenotyping during 131 
the Salivary Markers study (BD Vacutainers, Franklin Lakes, NJ, USA) before, during and 132 
after the 6-month mission in the ISS.  133 
Specifically, plasma samples from Integrated Immune were collected at L-180 (180 days 134 
before launch), L-45, FD-10 (10 days after launch - "Early"), FD-90 ("Mid"), FD-180/R-1 (last 135 
day in space, "Late"), R+0 (Upon return on earth) and R+30 from 15 ISS crewmembers. 136 
Plasma samples collected during the Salivary Markers study were drawn at L-180, L-60, FD-137 
10, FD-90, FD-180/R-1, R+0, R+18, R+33 and R+66 from 8 astronauts and 6 ground-based 138 
controls. Blood samples used for B-cell phenotyping were collected during Salivary Markers 139 
on 8 ISS crewmembers, in vacutainers supplemented with an acidified glucose nutrient 140 
solution (Acid-citrate dextrose) to maintain optimal cellular viability during sample return on 141 
Earth. Technical constraints did not allow for timely return of whole blood on earth at FD-142 
10, and consequently no B-cell phenotype data were measured at that timepoint.  143 
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A temperature-controlled environment (temperature range: 6-24°C) was maintained during 144 
the 24-36 hours of sample storage/transport to the laboratories at NASA-JSC and the 145 
University of Houston. Upon arrival to the respective laboratories, the plasma samples were 146 
centrifugally separated from whole blood and stored at -80°C and B-cell phenotype was 147 
characterized using whole blood samples from the ACD tubes. Cryopreserved plasma samples 148 
were transported to the ImmunoEnergetics laboratory at Louisiana State University, and 149 
freshly isolated B-cells phenotypes were characterized on a BD Accuri C6 flow cytometer (BD 150 
Accuri, Ann Arbor, MI, USA) at the University of Houston. Lymphocyte counts were 151 
determined using a Mindray BC-3200 auto hematology analyzer (Mahwah, NJ, USA). 152 
Urine and saliva samples were collected during the Integrated Immune study to determine 153 
CMV, EBV and VZV viral load in astronauts throughout the mission; results reported 154 
elsewhere (35, 36). In brief, aliquots of urine were sampled from a 24-hours urine pool at 155 
each of the aforementioned timepoint, and fasting saliva samples were collected using sterile 156 
Salivette cotton rolls (Sardstedt, Newton, NC) immediately upon awakening. The urine 157 
samples were frozen until return to Earth, while the salivettes were stored in stability buffer 158 
(0.5% SDS, 10mM Tris-Cl and 1mM EDTA) at room temperature for up to 2 weeks before 159 
return to Earth for subsequent analysis (37). Viral DNA was extracted and quantified by Dr. 160 
Mehta at NASA JSC by polymerase chain reaction as described previously (38).  161 
2.3 B-cell phenotyping 162 
B-cells were labeled with directly-conjugated monoclonal antibodies and analyzed using 4-163 
color flow cytometry as previously described (54). Briefly, aliquots of 50µL of whole blood 164 
were incubated with 5µL of each mAb for 30 minutes at room temperature in the dark. The 165 
following mAb were used to stain the cells: anti-CD20-FITC clone #LT20, anti-CD43-PE 166 
clone #84-3C1 (eBioscience, San Diego CA USA), anti-IgD-PE clone #IA6-2, anti-IgM-PE 167 
clone #G20-127 (BD Pharmingen, San Diego CA USA), anti-IgG-PE clone #H2 (Southern 168 
Biotech, Birmingham AL USA), anti-CD27-PerCP clone #0323, anti-CD25-APC clone 169 
#CD25-4E3, anti-CD5-APC clone #L17F12 and anti-CD38-APC clone #HIT2 (eBioscience, 170 
San Diego CA USA). Using these mAbs, CD20+ B-cells were classified into immature 171 
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(CD20+/CD43-/CD27-/IgD-), naive/transitional (CD20+/CD43-/CD27-/IgD+), memory B-cells 172 
(CD20+/CD43+/CD27+/CD38-), plasmablasts/plasma cells (CD20+/CD43+/CD27+/CD38hi), B1 173 
cells (CD20+/CD43+/CD27+/CD5-), regulatory B-cells (CD20+/CD43+/CD27-/CD5+), IgG+ 174 
memory B-cells (CD20+/CD27+/IgG+) and IgM+ B-cells (CD20+/CD27+/IgM+) (Table 1). 175 
Following incubation, erythrocytes were lysed by increased osmotic pressure induced by the 176 
addition of 500µL of RBC lysis buffer (eBioscience, San Diego, CA, USA) for 20 minutes at 177 
room temperature. Samples were then washed twice with PBS and resuspended in 250µL of 178 
PBS to be analyzed on a Accuri C6 flow cytometer. Flow cytometry analysis was conducted 179 
on the Accuri proprietary flow cytometry analysis software. Total cell numbers of each B-cell 180 
subset were determined by multiplying the percentages of cells expressing each marker of 181 
interest by the total lymphocyte count. 182 
2.4 Immunoglobulin analyses 183 
Plasma samples from the 23 crewmembers (N “integrated immune”=15; N “salivary 184 
markers”=8) were  thawed and a total volume of 100μL were analyzed for Kappa and Lambda 185 
free light chains (FLC) using commercially-available enzyme linked immunosorbent assays 186 
(ELISA) (Seralite®, Abingdon Health, Oxford, UK) using previously published methods (7). 187 
Briefly, diluted plasma samples were incubated in 96 well plates pre-coated with either anti-188 
Kappa or anti-Lambda FLC monoclonal antibodies at room temperature for 60 minutes. 189 
Following initial incubation, the wells were washed four consecutive times, and incubated 190 
with HRP-labeled anti-Kappa or anti-Lambda detection antibody for 30 minutes at room 191 
temperature. After another washing step, the presence of Kappa or Lambda FLC in the plasma 192 
samples were detected using a colorimetric reaction and read on a SpectraMax i3x plate 193 
reader (San Jose, CA, USA). The color intensity was directly correlated with the Kappa and 194 
Lambda FLC concentration in the samples. Plasma cystatin-C was measured with 195 
commercially-available ELISA (R&D Systems, Minneapolis, MN, USA) and used to calculate 196 
estimated glomerular filtration rate (eGFR) throughout the missions based on an established 197 
algorithm (47). This estimate of renal function was used to account for changes in renal 198 
clearance of FLC in response to spaceflight.  199 
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Total IgA, IgM and IgG were measured in a total of 150μL of thawed plasma sample from all 200 
astronauts and corresponding controls using commercially available ELISA kits (eBioscience, 201 
San Diego, CA, USA).  202 
2.5 Statistical Analysis 203 
A longitudinal, repeated measures design was utilized to determine the effects of long-term 204 
exposure to microgravity on proportions and numbers of the different B-cell subsets, Kappa 205 
and Lambda FLC and immunoglobulin levels. Linear mixed models were used to evaluate 206 
potential differences in the main and interaction effects of time (L-180, L-45 to 60, early 207 
flight, mid-flight, late flight, R+0, R+1, R+18, R+30 to 33, and R+66) after controlling for 208 
potential change in eGFR. When a significant time effect was observed, post-hoc tests were 209 
performed with Bonferroni correction. Data is presented as means ± standard error. All 210 
statistical analyses were performed using SPSS version 24 (IBM Corp., Armonk, NY) and 211 
significance was set at p < 0.05. 212 
 213 
3. Results 214 
3.1 Effect of long-duration spaceflight on circulating B-cell subsets   215 
Cell counts for the different B-cell subsets isolated from crewmembers throughout the 216 
Salivary Markers study are presented in Table 2. There was no change in the percentages of 217 
total B-cells within the lymphocyte population or in the total number of B-cells during the 6 218 
months mission (FB-cell Frequency=1.603; pB-cell Frequency=0.142 and FB-cell count=0.248; pB-cell count=0.972). 219 
Furthermore, long duration spaceflight was not associated with any statistically significant 220 
change in Plasma cells, Immature, Naïve/Transitional, Memory, Regulatory and B1-cells 221 
(p>0.05) in crewmembers. 222 
3.2 Long-duration spaceflight and blood immunoglobulins 223 
 3.2.1 Plasma intact immunoglobulins concentration during a 6-month mission in the 224 
ISS 225 
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There was no change in plasma IgG and IgM concentrations in astronauts throughout the 226 
mission (p>0.05). The impact of long-duration spaceflight on total plasma immunoglobulin 227 
concentrations is presented in Table 3. Astronauts exhibited an increase in plasma IgA during 228 
flight, when compared to baseline values (L-60/45) (F=7.077; p<0.001). Upon return on Earth, 229 
plasma IgA concentrations decreased from in-flight levels, and were back to pre-flight values 230 
(L-60/L-45) during recovery (R+30) (p=0.047). All changes withstood adjustment for latent 231 
viral reactivation status and DNA load, along with eGFR.  232 
 3.2.2 Plasma FLC concentration during a 6-month mission in the ISS 233 
The effects of long-duration spaceflight on Kappa (κ) and Lambda (λ) FLCs, along with the 234 
ratio of κ/λ and total FLC are presented in Figure 1. There was no effect of spaceflight on 235 
plasma κ FLC (p>0.05), and only a minor decrease in the concentration of plasma λ FLC was 236 
observed immediately upon return on Earth (R+0) in crewmembers when compared to in-237 
flight plasma λ FLC concentrations (Early: p=0.03; Mid: p=0.005 and Late/R-1: p=0.012). The 238 
preferential reduction in plasma λ FLC at landing without any change in plasma κ FLC 239 
concentration led to a minor decrease in κ/λ ratio at the Mid-flight timepoint when compared 240 
to baseline L-60/L-45 and return R+0 and R+30 κ/λ ratio (pL-45= 0.029; pR+0= 0.037; pR+18=0.053 241 
; pR+33=0.037). As plasma FLC levels can be impacted by altered production from plasma cells 242 
and/or impaired clearance from renal metabolism, Cystatin C was measured to calculate 243 
estimated glomerular filtration rate (eGFR) (1) and account for variation in renal function 244 
during spaceflight. There was no change in kidney function during flight (p>0.05), however 245 
post-flight eGFR values (R+30) were significantly lower than pre-flight values (L-60/L-45) 246 
(p=0.015). Subtle changes in plasma FLC withstood adjustment for eGFR. 247 
In related analyses, we explored whether latent viral reactivation was associated with FLC 248 
levels in blood. Cytomegalovirus (CMV), Epstein-Barr Virus (EBV) and Varicella Zoster Virus 249 
(VZV) reactivation status and viral DNA load from a subset of samples (Integrated Immune 250 
study) were included in the model as covariates. The rate and magnitude of latent viral 251 
reactivation observed in the Integrated Immune cohort is described elsewhere (51). In brief, 252 
47% (7/15) of astronauts exhibited CMV reactivation at any point during the mission, 73% 253 
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(11/15) of astronauts exhibited EBV reactivation at any point during the mission and 60% 254 
(9/15) of astronauts exhibited VZV reactivation at any point during the mission. There was no 255 
difference in plasma κ and λ FLC concentrations in astronauts who exhibited CMV and EBV 256 
reactivation at any point during the mission (p>0.05), and there was no association between 257 
CMV and EBV DNA load and plasma FLC at any timepoint (p>0.05). When VZV DNA load 258 
was included in the model, the greater plasma λ FLC concentration observed in-flight when 259 
compared to post-flight values was associated with the magnitude of VZV reactivation (FVZV 260 
DNA load = 4.937; pVZV DNA load = 0.029).  261 
 262 
4. Discussion 263 
The rapid progress made in aerospace technologies over the past 50 years has dramatically 264 
increased the scope and duration of manned space exploration missions. In addition to 265 
providing novel technological challenges, the safe implementation of exploration-class 266 
missions requires a profound understanding of the impact that prolonged exposure to space 267 
environments has on astronaut’s biology and health. In particular, numerous studies have 268 
raised concerns about the potential clinical risks associated with reported immune 269 
impairments observed during spaceflight (10, 11, 14, 50), such as reduced T-cell (25, 26, 34) 270 
and NK-cell functions (46), sustained production of pro-inflammatory cytokines (15, 35), 271 
altered neutrophil and monocyte microbicidal activity (30, 31), diminished anti-microbial 272 
protein concentration and increased rate and magnitude of latent viral reactivation (36, 51). 273 
However no study to date has attempted to comprehensively characterize the impact of long-274 
duration spaceflight on humoral immunity in humans. The goal of this study was to identify 275 
changes in a broad range of phenotypically distinct B-cell subsets, along with secreted 276 
immunoglobulins and free light chains in astronauts who completed 6-months on the ISS. We 277 
found no change in the number of total B-cells in response to spaceflight, however there was 278 
a trend for increased Memory B-cells during spaceflight, when compared to baseline values. 279 
Contrary to supposition, only marginal changes were observed in soluble biomarkers of B-cell 280 
homeostasis during spaceflight. Indeed, we found no effect of spaceflight on plasma κ FLC, 281 
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IgG and IgM levels, and only modest changes to plasma λ FLC concentrations. Interestingly, 282 
long-duration spaceflight increased plasma IgA levels, which considering the correlation 283 
between mucosal and plasma IgA (55), may represent alterations in mucosal immunity. 284 
Spaceflight has been shown to alter human and animal leukocyte distribution (12, 48), but the 285 
majority of studies were focused on T-cells and NK-cells (22, 46), and were limited to either 286 
short-duration missions (8-15 days) (23, 52) or to comparisons between pre- and post-flight. 287 
Our data are in accordance with previous findings showing that total B-cell counts and 288 
proportion within the lymphocyte compartment are not affected by long-duration spaceflight 289 
(46). However, the more advanced and detailed phenotypic analysis performed in this study 290 
highlighted for the first time that spaceflight does not have a detrimental impact on the 291 
phenotypic composition of the B-cell compartment. Indeed, memory B-cell counts changed 292 
modestly in-flight, while the number of naive/transitional and regulatory B-cells remained 293 
unchanged during the mission. Animal studies have shown that short-duration spaceflight 294 
(41) and ground-based analogs to spaceflight such as hind limb unloading (32) had deleterious 295 
impacts on immune cell phenotypes in the bone marrow and led to a reduction in de novo 296 
generation of B-cells (32) and total splenic B-cells number (21). As both bone marrow 297 
progenitor cells (18) and B-cells are known to respond to acute stressors, such as intense 298 
exercise (54), it can be hypothesized that the changes in B-cell lymphopoiesis observed in 299 
animals immediately after short-duration spaceflight may be due to a variety of factors other 300 
than microgravity, including landing-associated stressors, rather than exposure to the space 301 
exposome.  302 
Effective humoral responses rely on B-cell activation, differentiation and antibody output. 303 
Although there was no effect of spaceflight on the number of circulating plasma cells in 304 
astronauts, it is interesting to note that they had a greater amount of B1 cells than ground-305 
based controls (data not shown). As B1 cells have recently been characterized as pre-306 
plasmablasts (9), a greater circulating number could be associated with increased capability to 307 
produce antibodies following activation. Conflicting data exist on the effect of spaceflight on 308 
immunoglobulin outputs, with some studies showing a reduction in in vitro IgG production 309 
in response to altered gravity (19), while others showed no change from baseline in IgG 310 
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production after a 10-15 days flight (52, 56), and no alteration in the B-cell repertoire of 311 
unimmunized animals (58). Our data are in partial agreement with the current literature, as 312 
we found no difference in total plasma IgG and IgM at any point in the mission, even after 313 
controlling for latent viral reactivation and DNA load. Interestingly however, astronauts 314 
exhibited an increase in total plasma IgA during flight. Elevated plasma IgA have been 315 
observed in the urodele amphibian Pleurodeles waltl exposed to microgravity for 6 months 316 
(5), but also in rodents and human subjects under chronic psychological and physiological 317 
stress (20, 60), similar to those experienced by the astronauts on board the ISS. Furthermore, 318 
although the in-flight increases in plasma IgA concentrations were statistically significant 319 
when compared to baseline values, astronauts' plasma IgA levels did not exceed the normal 320 
clinical range observed on Earth (59). Consequently, the fluctuations in plasma IgA observed 321 
in this study are likely attributable to long-duration exposure to spaceflight-associated 322 
psychological and operative stressors rather than to alterations in B-cell function.  323 
The immune impairments associated with prolonged exposure to the myriads of stressors 324 
specific to the spaceflight environment are known to result in increased latent CMV, EBV 325 
and VZV reactivation (35, 36, 51). However, no study to date has attempted to determine 326 
whether potential alterations in B-cell activation and function could play a role in latent viral 327 
reactivations in space. While our data did not show any biologically-relevant change in total 328 
plasma immunoglobulin concentrations in response to spaceflight, it could be argued that the 329 
relatively long half-life of intact plasma Ig (around 21 days) curtails their sensitivity at 330 
detecting changes in B-cell function (16). As such, we sought to determine changes in κ and λ 331 
immunoglobulin Free Light Chains, a more sensitive barometer of immune competency with 332 
short half-life (κ: 2-4 hrs; and λ: 3-6 hrs) due to rapid renal clearance (16). Plasma κ FLC 333 
levels remained unchanged during the missions, however there was a slight decrease in the 334 
concentration of plasma λ FLC immediately upon return on Earth (R+0) in crewmembers 335 
when compared to in-flight plasma λ FLC concentrations. While this reduction in λ FLC at 336 
R+0 when compared to in-flight values reached statistical significance, no crewmember 337 
reached clinically significant low-levels of λ FLC (29). As there was no change in kidney 338 
function in-flight, this preferential reduction in plasma λ FLC is not due to increased renal 339 
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clearance. However, while there was no effect of CMV and EBV reactivation on λ FLC 340 
concentrations, the magnitude of VZV reactivation during flight was associated with the 341 
greater levels of λ FLC observed at the same timepoints. This discrepancy in response 342 
between plasma κ and λ FLC, could be explained by the difference in size between both light 343 
chains. Indeed, although κ FLC are produced in greater quantities than λ FLC during 344 
antibody synthesis (57), the larger size of the dimeric λ FLC impedes their clearance by the 345 
kidney (16). Our results suggest that B-cell ability to produce FLC and consequently 346 
immunoglobulins in response to a viral or vaccine challenge in space remain intact. It should 347 
however be noted that, while we measured the quantity of plasma κ and λ FLC and total 348 
Immunoglobulins in crewmembers, we did not characterize the quality of these antibodies. 349 
Animal studies have indeed showed that while similar quantities of antibodies could be 350 
produced in response to antigenic challenge in space (3), the quality of the produced 351 
antibodies remained inferior to those produced on earth (2). Consequently, although the 352 
present study shows that B-cell homeostasis appears to be preserved during long duration 353 
spaceflight, it could be hypothesized that sub-optimal immune responses could still be 354 
observed upon antigenic challenge in space.   355 
One limitation of our study lies in its retrospective nature. These results were obtained from 356 
samples collected during two previously completed NASA studies, and all plasma 357 
immunoglobulin and FLC analysis were performed on previously archived samples. As such, 358 
we were unable to measure the antibody response to a specific vaccine, but rather measured 359 
B-cell homeostasis during long duration spaceflight. Furthermore, the changes in B-cell 360 
number and phenotype during spaceflight were only characterized on the Salivary Markers 361 
cohort (n=8). Technical constraints unique to spaceflight research prevented the immediate 362 
analysis of the isolated B-cell populations. To mitigate this limitation, we performed 363 
validation work in our laboratory prior to this study, and found that B-cell number and 364 
phenotype remained unaltered for 48 hours when collected from vacutainers supplemented 365 
with an acidified glucose nutrient solution. Finally, we also collected blood samples from 366 
ground-based controls to parallel samples collected on the ISS, thus controlling for any 367 
potential ex vivo aging of the blood samples. Unfortunately however, as the ground-based 368 
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control subjects were recruited to ensure assay validity, rather than to serve as paired-controls 369 
with each astronauts, they were not age- or sex-matched with the different crewmembers. 370 
Future studies should attempt to recruit populations of ground-based controls that closely 371 
match the astronaut population to further reduce the effects of various confounding factors 372 
(age, sex, fitness level etc...) on the observed changes in immune function during spaceflight.  373 
In conclusion, this is the first study to comprehensively show that long-duration spaceflight 374 
in human astronauts has no – or very limited – effect on B-cell number, phenotype and 375 
antibody output. These important results suggest that plasma immune competency is 376 
maintained in microgravity, and that future in-flight vaccine-based countermeasures are 377 
likely to be efficient at further protecting astronauts from immune dysregulation and 378 
symptomatic latent viral reactivations during prolonged exploration class missions. 379 
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Figure 1. Changes in Kappa κ (A) and Lambda λ (B) Free Light Chains in 6 months ISS astronauts 
(n=23). The ratio of κ/λ and total Free Light Chains are presented in panel C and D respectively. 
Mean values are presented ± SEM. Significant differences between immediately post-flight 
values (R+0) (* p<0.05) and baseline values (L-45) (a p<0.05) 
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Table 1. Phenotypic characterization of the different B-cell subsets 
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Cell Type Phenotype Reference 
B-cells CD20+ (Leandro 2013) 
Immature B-cells CD20+/CD43-/CD27-/IgD- (Inui et al. 2015; Sims et al. 2005; Wei, Jung, and Sanz 2011) 
Naïve/Transitional B-
cells CD20+/CD43-/CD27-/IgD+ 
(Inui et al. 2015; Sims et al. 
2005; Wei, Jung, and Sanz 2011) 
IgM+ B-cells CD20+/CD27+/IgM+ (Berkowska et al. 2011) 
Memory B-cells CD20+/CD43+/CD27+/CD38- (Quach et al. 2016) 
IgG+ memory B-cells CD20+/CD27+/IgG+ (Berkowska et al. 2011) 
B1 cells CD20+/CD43+/CD27+/CD5- (Griffin, Holodick, and Rothstein 2011) 
Regulatory B-cells CD20+/CD43+/CD27-/CD5+ (Mauri and Menon 2015) 
Plasmablasts/Plasma 
cells CD20+/CD43+/CD27+/CD38
hi (Quach et al. 2016) 
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Table 2. Changes in the numbers (cells/100μL) of B lymphocyte lineage cells in 6 months ISS crewmembers (n=8). Average values are 
presented ± SD.  
 
 
 
 
 
 
 
 
L-180 L-60 FD-90/Mid-Flight R-1/Late-Flight R+0 R+18 R+33 R+66
Total B-cells
Cells/100μL
ISS Crewmembers (n=8) 12128 ± 4080 15316 ± 3036 21892 ± 12747 24920 ± 14955 19865 ± 13955 14279 ± 6157 13831 ± 3272 11856 ± 4376 0.248 (0.972)
% Lymphocytes
ISS Crewmembers (n=8) 10 ± 4 12 ± 3 13 ± 4 11 ± 4 13 ± 7 11 ± 5 11 ± 4 9 ± 4 1.603 (0.142)
Immature B-cells
ISS Crewmembers (n=8) 482 ± 271 625 ± 568 2618 ± 2936 2508 ± 3785 2322 ± 3534 1022 ± 1233 866 ± 768 602 ± 645 0.665 (0.702)
Naïve/Transitional B-cells
ISS Crewmembers (n=8) 7091 ± 3751 9787 ± 4250 11083 ± 5605 12896 ± 6237 11196 ± 7842 7855 ± 3706 8045 ± 3292 7044 ± 3447 0.626 (0.733)
IgM+  B-cells
ISS Crewmembers (n=8) 53 ± 155 11 ± 13 16 ± 22 29 ± 45 34 ± 46 6 ± 9 10 ± 11 11 ± 11 0.702 (0.670)
Memory B-cells
ISS Crewmembers (n=8) 179 ± 158 208 ± 133 327 ± 243 409 ± 310 381 ± 327 202 ± 141 394 ± 477 196 ± 122 1.878 (0.080)
IgG+ memory B-cells
ISS Crewmembers (n=8) 74 ± 177 38 ± 29 67 ± 63 41 ± 46 42 ± 43 57 ± 95 61 ± 73 28 ± 21 1.004 (0.432)
B1 cells
ISS Crewmembers (n=8) 123 ± 117 211 ± 256 225 ± 177 283 ± 357 242 ± 216 211 ± 171 167 ± 221 306 ± 383 0.932 (0.485)
Regulatory B-cells
ISS Crewmembers (n=8) 129 ± 104 177 ± 64 288 ± 240 269 ± 151 312 ± 494 152 ± 51 252 ± 206 202 ± 124 0.943 (0.476)
Plasmablasts/Plasma cells
ISS Crewmembers (n=8) 104 ± 86 178 ± 155 169 ± 102 197 ± 177 185 ± 202 161 ± 157 99 ± 93 173 ± 233 0.225 (0.979)
Main Effect of Time 
F-statistic 
(p value)
Sample Timepoint
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Table 3. Changes in plasma IgA, IgM and IgG in Astronauts before, during and following 6 months in the ISS (n=23). Average values 
are presented ± SD Significant differences from baseline pre‐flight values (L‐180 and L‐60/L‐45) are represented with * (p<0.05). 
 
 
L‐180 L‐60/L‐45 Early‐Flight FD90/Mid‐Flight R‐1/Late‐Flight R+0 R+18 R+30/R+33 R+66
IgA (mg/dL) ± SD Crewmembers (n=23) 131.51 ± 63.73 112.73 ± 49.64 126.60 ± 58.05 * 136.38 ± 68.12 * 140.58 ±75.08 * 126.64 ± 59.56 103.14 ± 32.67 112.46 ± 55.11 101.73 ± 27.51
IgG (mg/dL) ± SD Crewmembers (n=23) 1218.41 ± 231.66 1190.41 ± 253.88 1181.47 ± 310.80 1235.41 ± 277.07 1249.98 ± 298.99 1184.38 ± 209.64 1359.33 ± 304.05 1226.67 ± 399.88 1267.50 ± 255.92
IgM (mg/dL) ± SD Crewmembers (n=23) 373.51 ± 546.67 408.84 ± 530.97 476.08 ± 665. 62 422.57 ± 476.36 410.57 ± 491.51 346.95 ± 360.77 651.04 ± 751.93 295.78 ± 268.07 471.20 ± 324.15
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